No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GH240816C25000
- 8.30
- +1.40+20.29%
15min DelayClose Jul 23 16:00 ET
8.60High8.30Low
8.60Open6.90Pre Close2 Volume101 Open Interest25.00Strike Price1.69KTurnover113.00%IV1.90%PremiumAug 16, 2024Expiry Date7.68Intrinsic Value100Multiplier24DDays to Expiry0.62Extrinsic Value100Contract SizeAmericanOptions Type0.8592Delta0.0235Gamma3.82Leverage Ratio-0.0467Theta0.0130Rho3.28Eff Leverage0.0188Vega
Intraday
- 5D
- Daily
News
Express News | Guardant Health Launches Enhanced Guardant360 Test On Guardant Infinity Platform; New Test Covers 10 Times More Genes And Quantifies Tumor Burden With 10 Times Higher Sensitivity; Medicare And Major Private Payers Cover Test For Comprehensive Genomic...
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test, Further Extending Its Best-in-Class Performance
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Guardant Health Appoints Oncology Expert to Board of Directors
Express News | DR. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
Guardant Health Is Maintained at Buy by B of A Securities
Comments
Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)? 1
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades $Snowflake(SNOW.US$ to Peer Perform From Outperform
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
18
1
Read more